(0.32%) 5 116.07 points
(0.32%) 38 363 points
(0.35%) 15 983 points
(-0.94%) $83.06
(5.56%) $2.03
(0.34%) $2 355.20
(0.41%) $27.65
(4.02%) $959.20
(-0.25%) $0.932
(-0.40%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
@ $0.735
発行日: 15 2月 2024 @ 04:11
リターン: -28.87%
前回のシグナル: 2月 14 - 05:21
前回のシグナル:
リターン: 6.03 %
Live Chart Being Loaded With Signals
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation...
Stats | |
---|---|
本日の出来高 | 480 794 |
平均出来高 | 2.44M |
時価総額 | 106.44M |
EPS | $0 ( 2024-03-13 ) |
次の収益日 | ( $-0.220 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.350 |
ATR14 | $0.00200 (0.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-24 | Pooler Amy | Sell | 2 209 | Common Stock |
2024-02-25 | Pooler Amy | Sell | 2 459 | Common Stock |
2024-02-24 | Willoughby Scott B. | Sell | 4 379 | Common Stock |
2024-02-25 | Willoughby Scott B. | Sell | 3 453 | Common Stock |
2024-02-24 | Dubois-stringfellow Nathalie | Sell | 5 474 | Common Stock |
INSIDER POWER |
---|
3.11 |
Last 100 transactions |
Buy: 7 300 210 | Sell: 7 415 564 |
ボリューム 相関
Sangamo Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
BOCH | -0.891 |
ARDX | -0.869 |
HEES | -0.86 |
OSUR | -0.859 |
STRL | -0.859 |
ATAK | -0.858 |
LRFC | -0.857 |
BCOR | -0.857 |
STAY | -0.857 |
SCRM | -0.854 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sangamo Therapeutics Inc 相関 - 通貨/商品
Sangamo Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $176.23M |
総利益: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2023 |
収益: | $176.23M |
総利益: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2022 |
収益: | $111.30M |
総利益: | $99.19M (89.12 %) |
EPS: | $-1.250 |
FY | 2021 |
収益: | $110.70M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。